Owen A O'Connor MD

PubMed

• 16 citations
  Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
  Matthew S. Davids, Owen A. O'Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S. Fenske
  Blood Advances. 2021-09-21
• 2 citations
  Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance.
  Kana Oiwa, Naoko Hosono, Rie Nishi, Luigi Scotto, Owen A. O'Connor
  BMC Cancer. 2021-07-31
• 7 citations
  Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways.
  Luigi Scotto, Cristina Kinahan, Eugene Douglass, Changchun Deng, Maryam Safari
  Molecular Cancer Therapeutics. 2021-06-09

Abstracts/Posters

• Targeting eIF4A Using MZ-735 Potently Induces Cell Death in Lymphoma Cells and Rapidly Represses mRNA Translation at the Global Level and in C-MYC and Other Oncogenes
  Owen O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Co...
  Owen O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)
  Owen A. O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype
  Owen A. O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Casein Kinase 1 Delta Is a Novel Regulator of mRNA Translation and Druggable Target in Aggressive Lymphomas
  Owen O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis
  Owen A. O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators
  Owen A. O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Effect of epigenetic modifier-based combinations on efficacy in patients with peripheral T-cell lymphoma (PTCL): Deciphering impact of mutations in epigenetic operatio... 
  2019 ASCO Annual Meeting - 6/1/2019
• Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Exploring the Present and Future of BTK Inhibition in B-Cell Malignancies: Expert Insights on Practical Implications for Patient Management 
  60th American Society of Hematology Annual Meeting - 11/30/2018